Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$LEAS simple terms as I see it, nobody has lost anything. The ability to buy more was disabled for retail by moving trading to EM, temporarily. Retail can still sell however.
Once EM period is over and the merger complete, new shares will be issued to everyone through some conversion rate (TBD) and you can resume buying/selling of the new shares.
April 18 was last day for retail to buy LEAS openly. Now you either sell or wait for the new shares.
Sound correct? Feel free to correct me, as I am not an expert by any means.
The company has never stated a conversion ratio. That 1:174 crap is just "speculation."
The company did say they were going to essentially have the owners of ANEW (those who invested in it prior to inhabiting the LEAS shell) own 99% of the equity by effecting a 1-2500 RS then converting the preferred shares into common. With the RWOD merger, they later said they no longer needed the RS, and they can distribute the 6M RWOD shares anyway they want since they control the vote. That is reinforced by the CEO getting 1.4M of the 6M RWOD shares.
1.174 conversion meaning what? When the name will change ?
That was the correct answer..........Kudos...........
Z
From what I read, it’s a 1:174 conversion , Rolled into an actual NASDAQ company that will be profitable
Fidelity won't let you buy leas anymore
You can always sell what you have in expert market, at least with E*TRADE and Charles Schwab, but not buy. But what’s the point? Why not Hold for the conversion and the up listing
Leas is not on corporate action....
Maybe but I'm holding for gold.
anew is in Nyse
To get rid of us.Simple...this is what they were waiting for.That is why were kicking the can...
Then why on my other share that change market to expert transfer name and was applied to us?
Wena but not for Leas but Rwod.
The new symbol is supposed to be WENA, which isn’t trading yet.
This is the shareholders value as mentioned Dr.
Yes. It doesn't matter whether it's in the gray market or not. We'll just have to wait what the convention rate is.
It looks like all merger was just one big thief
Are there shares supposed to change to the new Stock name? I had another shares that merge and my stock were transfer to the new symbol
So they finished the merger, and made LEAS shares, worthless, nice
Looks like LEAS shareholders should have sold and purchased RWOD. At least, for now, RWOD is alive and doing great in the premarket.
Now that LEAS is expert market my broker is requiring a call to place a sell. Can't win them all. Hope the good Dr enjoys his retirement profits.
and what about Leas shares ?? We are in the Expert market now.Maybe it is irrelevant now I do not know.
Redwoods Acquisition Corp. (RWOD) shares surged 72% after Thursday's 3.2% drop.
That’s a nice sign.
RWOD closed yesterday at 7.99 and now premarket is up at 12.78. 1.2 million shares! Crazy.
We are in the Expert Market.What next ??? 0.0001 ???
Well merger is here so idc
Always someone around to say I told you so!!
Old enough to do stocks…
Wow, an OTC company actually followed through on their merger, incredible.
Do we think it hits tomorrow
Curious that myself, don’t see anything that tells me that.
Whats the conversion!!
Is tomorrow the day I wake up to WENA shares in my account and $142,800?
Is this going to em??
Strange.More buys than sells and 50% down
I was waiting for the god damn fucking merger that was “supposedly” valued at 5 cents instead starting at the disaster that just happened. Fuck u all honestly. Why dis the pos dr approve merger if his plan was to fuck retail?
That’s why you take profit to get your original investment back and ride profit. You’ve had plenty of chances to double or triple your money, and if you took none off the table that’s on you.
Followers
|
900
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
155603
|
Created
|
10/19/07
|
Type
|
Free
|
Moderators |
Medical product development and commercialization. The Company recently acquired five generic oncology drugs approved and manufactured in Germany and they plan to gain approval for these drugs in the US in 2023. The Company is preparing for a pivotal Phase 3 study of an anti-cancer antibody product that is highly similar to Genentech/Roche's brand name Avastin (bevacizumab), the Company has licensed a needle-free jet injector for drug delivery, and the Company is in the pre-clinical stages of development of a gene therapy product candidate based on the delivery of a human alpha-Klotho gene and protein to prevent and/or treat neurodegenerative diseases such as Alzheimer's and Lou Gehrig's disease (ALS). Other product candidates will stem from these platform technologies of pharmaceuticals, biologics, and gene therapy.
The Company's medical R&D facilities are in the U.S. (near the University of Nebraska Medical Center, Omaha, Nebraska) and in Barcelona, Spain (Autonomous Universitat de Barcelona). Each R&D facility is comprised of over 4,000 sq ft of R&D and office space, currently leased and equipped with research equipment, incubators, tissue culture facilities for production of plasmid DNA, HEPA-filtered hoods for aseptic handling, and testing equipment (PCR, spectrophotometers, microscopes, etc). The generic oncology drugs are manufactured in Germany. With future funding, the Company plans to acquire or build a GMP manufacturing facility to supply novel plasmid DNA ("transgenes") to be used in gene therapy programs, to provide contract manufacturing revenue, and for commercial product manufacturing.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |